Select Page

Ness Ziona Aerial View, by Amos Meron[/caption] BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. BiondVax’s technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax’s Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company’s Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone, a blockbuster drug for the treatment of multiple sclerosis. The company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, for developing, manufacturing and commercializing its flu vaccine.]]>